Infusion Drug Delivery News

  1. Melbourne-Developed Drug Delivery Platform Delivers ‘Impressive’ Results In International Bowel And Ovarian Cancer Trial 9/12/2023

    A ground-breaking nanoscale drug delivery technology used to enhance the safety and performance of cancer drugs has been credited with “impressive” results in two of Australia’s most common cancers – colorectal (bowel) and ovarian cancer.

  2. Race Executes Agreement With Ardena For GMP Manufacturing Of RC220 7/12/2023

    Race Oncology Limited ("Race") is pleased to announce that it has signed an agreement with leading global contract development and manufacturing organisation (CDMO), Ardena Holding NV (Ardena) to provide additional Good Manufacturing Practice (cGMP)-standard manufacturing capability for Race's flagship intravenous (IV) formulation of bisantrene, RC220.

  3. Acasti Announces WuXi Clinical As CRO To Conduct STRIVE-ON Pivotal Phase 3 Safety Trial For GTX-104 In aSAH Patients 7/10/2023

    Acasti Pharma Inc. (Nasdaq: ACST) ("Acasti" or the "Company"), a late-stage, biopharma company advancing GTX-104, today announced WuXi Clinical Development, Inc. ("WuXi Clinical"), a wholly owned subsidiary of WuXi AppTec, a global Contract Research Organization (CRO), will conduct Acasti's STRIVE-ON Phase 3 safety trial for GTX-104. GTX-104 is Acasti's novel, injectable nimodipine formulation for intravenous infusion (IV) that addresses high, unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH).

  4. Ascendia Pharmaceuticals Develops Novel Nanoemulsion IV Formulation For Clopidogrel That Received IND Approval 6/27/2023

    Ascendia Pharmaceuticals CEO Jim Huang, Ph.D. announces Ascendia's patented EmulSol® nanotechnology has been used to develop a novel nanoemulsion IV formulation for clopidogrel that has received Investigational New Drug (IND) approval from the Food & Drug Administration (FDA).

  5. Viridian Therapeutics Announces Partnership With Drug Delivery Innovator Enable Injections 5/8/2023

    Viridian Therapeutics, Inc., a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced a new partnership with Enable Injections, a company developing and manufacturing the enFuse® innovative wearable drug delivery system for volumes of up to 25mL.

  6. Scaling Up Capacity, Eitan Medical Opens New Manufacturing Facility Bolstered by Semi-Automated Production Lines 3/22/2023

    Eitan Medical, a global leader in advanced infusion therapy and drug delivery solutions across the care continuum, announced today the opening of its new manufacturing facility at the company’s headquarters. On-site manufacturing will support Eitan Medical’s production scale of its Pharmaceutical Solutions division.

  7. Catalent And Bhami Research Laboratory Enter Into Licensing Agreement For Technology To Deliver High-Concentration Biologics Subcutaneously 3/16/2023

    Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, and Bhami Research Laboratory (BRL), today announced a licensing agreement that will provide Catalent with access to BRL’s formulation technology to help enable the subcutaneous delivery of high-concentration biologic therapies.

  8. LIfT BioSciences And Minaris Regenerative Medicine Enter Into A Development And Manufacturing Partnership For N-LIfT Allogeneic Neutrophil Based Cell Therapy 2/16/2023

    LIfT BioSciences, a pioneering pre-clinical stage company moving into first-in-human trials with an allogeneic neutrophil progenitor based cell therapy, and Minaris Regenerative Medicine GmbH, a leading global contract development and manufacturing service provider for the cell and gene therapy industry, have entered into a development and manufacturing partnership for N-LIfT, LIfT’s first-in-class neutrophil progenitor based Leukocyte Infusion Therapy for the treatment of various cancer indications, including Pancreatic Cancer, Lung Cancer and other solid tumours.

  9. Elektrofi Announces Collaboration With Thermo Fisher Scientific To Strengthen Manufacturing Capabilities For Future Clinical Trials 2/7/2023

    Elektrofi, a biotechnology company focused on drug formulation and delivery innovations, today announced a strategic contract manufacturing agreement with Thermo Fisher Scientific to support clinical manufacture of Elektrofi’s breakthrough ultra-high concentration subcutaneous products.

  10. Oncorus Announces Research Collaboration With Daewoong Pharmaceutical For The Development Of Lipid Nanoparticle Formulations For mRNA Drug Candidates 1/4/2023

    Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, and Daewoong Pharmaceutical Co., Ltd. (KRX: 069620), a leading South Korean pharmaceutical company, today announced a research collaboration for the discovery and development of novel lipid nanoparticle (LNP) formulations for mRNA drug candidates.